Amazon UK sales up 90%: $2.27 million in TTM sales for the twelve months to November 2, 2026, up from approximately $1.19 million in the prior twelve months - 23% net margin on Amazon UK: the Amazon UK channel generated $525,000 in net profit after all direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT - 116,978 units sold on Amazon UK: an average of approximately 320 units per day - Record performance: July through October 2026 were the four strongest months to date on Amazon UK, each with sales above $215,000 - Efficient growth: advertising costs of only 2.4% of Amazon UK sales, with refunds below 1% - 72% growth expected: the Company expects Amazon UK sales of approximately $3.9 million over the next twelve months, an average of approximately $325,000 per month CHICAGO, IL / ACCESS Newswire / November 4, 2026 / Cosmos Health Inc. (" Cosmos Health " or the "Company") ( NASDAQ:COSM ), a diversified, vertically integrated global healthcare group, today provided an update on its Amazon UK business, reporting strong sales growth and profitability for the trailing twelve months ("TTM") from November 1, 2025 to November 2, 2026 . Amazon UK Performance Over the trailing twelve months, Amazon UK sales reached £1.71 million , or approximately $2.27 million , representing an increase of 90% compared with approximately $1.19 million in the prior twelve-month period. During the same period, the Company sold 116,978 units to customers in the United Kingdom , an average of approximately 320 units per day. This growth built steadily throughout the year. Monthly sales rose from approximately $144,000 in November 2025 to more than $215,000 in each of the last four months, July through October 2026 , the four strongest months in the Company's history on Amazon UK . Efficient and Profitable Growth Importantly, this growth has been achieved efficiently. Advertising costs represented only 2.4% of TTM sales, while refunds remained below 1% of sales. After all direct channel costs, including Amazon fees, cost of goods, shipping, advertising and VAT, Amazon UK generated net profit of approximately £395,000 , or approximately $525,000 , representing a net margin of approximately 23%. The Company believes these results reflect healthy underlying demand for its products, as well as an efficient and scalable sales channel. Supporting the Transition to a High-Margin Business Model Amazon UK has become an integral part of Cosmos Health's transition to a high-margin business model. The Company believes the channel's performance demonstrates the level of profitability that its proprietary brands can achieve when sold through efficient online channels. Outlook Building on this momentum, the Company expects Amazon UK sales over the next twelve months to grow by approximately 72% compared with the TTM period, to approximately $3.9 million , or an average of approximately $325,000 per month. The outlook is based on the Company's current sales trends and planned growth initiatives on the platform. CEO Commentary Greg Siokas , CEO of Cosmos Health , stated: "Amazon UK is now a multi-million-dollar business for us. Over the past twelve months, sales grew 90% to $2.27 million , and the last four months were our strongest ever on the platform. "Just as important is the quality of that growth. Advertising was only 2.4% of sales, refunds stayed below 1%, and we generated $525,000 in net profit, representing a net margin of approximately 23%. This is the kind of efficient, profitable growth that supports our transition to a high-margin business model. "Amazon UK is an integral part of our UK business. Looking ahead, we expect sales on the platform to grow by approximately 72% over the next twelve months, to around $3.9 million . We look forward to providing a broader update on our UK operations in due course." About Cosmos Health Inc. Cosmos Health Inc. (NASDAQ: COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, propriet